Last reviewed · How we verify
Technetium Tc99m Sestamibi
Technetium Tc-99m sestamibi is a radiopharmaceutical that accumulates in mitochondria of viable myocardial cells, allowing visualization of myocardial perfusion and viability via nuclear imaging.
Technetium Tc-99m sestamibi is a radiopharmaceutical that accumulates in mitochondria of viable myocardial cells, allowing visualization of myocardial perfusion and viability via nuclear imaging. Used for Myocardial perfusion imaging to assess coronary artery disease and ischemia, Evaluation of myocardial viability in patients with coronary artery disease, Risk stratification in patients with known or suspected coronary artery disease.
At a glance
| Generic name | Technetium Tc99m Sestamibi |
|---|---|
| Sponsor | Lantheus Medical Imaging |
| Drug class | Radiopharmaceutical imaging agent |
| Target | Mitochondrial membrane potential |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The drug is a lipophilic cationic complex that crosses cell membranes and localizes in mitochondria based on the negative membrane potential of viable cells. It is used as a tracer in single-photon emission computed tomography (SPECT) imaging to assess regional myocardial blood flow, detect ischemia, and evaluate cardiac viability. The degree of uptake correlates with myocardial perfusion and cellular viability.
Approved indications
- Myocardial perfusion imaging to assess coronary artery disease and ischemia
- Evaluation of myocardial viability in patients with coronary artery disease
- Risk stratification in patients with known or suspected coronary artery disease
Common side effects
- Headache
- Dizziness
- Chest discomfort (exercise-induced)
- Hypersensitivity reactions
Key clinical trials
- SPECT/CT for the Characterization of Renal Masses
- Tc99m Sestamibi Molecular Breast Imaging (NA)
- Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer (NA)
- DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer (EARLY_PHASE1)
- Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities (NA)
- A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (PHASE2)
- Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (PHASE3)
- 18F-fluorocholine PET/CT for Hyperparathyroidism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Technetium Tc99m Sestamibi CI brief — competitive landscape report
- Technetium Tc99m Sestamibi updates RSS · CI watch RSS
- Lantheus Medical Imaging portfolio CI